[1] Rudnick G, Clark J.From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters[J]. Neuroscience, 2006, 140(1):321-334. [2] Zhao S, Edwards J, Carroll J, et al.Insertion mutation at the C-terminus of the serotonin transporter disrupts brain serotonin function and emotion-related behaviors in mice[J]. Neuroscience, 2006, 140(1):321-334. [3] Fabre V, Beaufour C, Evrard A, et al.Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter[J]. Eur J Neurosci, 2000, 12(7):2299-2310. [4] Li Q, Wichems CH, Ma L, et al.Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice[J]. J Neurochem, 2003,84(6): 1256-1265. [5] Murphy DL, Fox MA, Timpano KR, et al.How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems[J]. Neuropharmacology, 2008, 55(6):932-960. [6] Compan V, Zhou M, Grailhe R, et al.Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice[J]. J Neurosci, 2004, 24(2):412-419. [7] Bockaert J, Claeysen S, Compan V, et al.5-HT4 receptors, a place in the sun: act two[J]. Curr Opin Pharmacol, 2011, 11(1):87-93. [8] Conductier G., Dusticier N Lucas G., et al.Adaptive changes in serotonin neurons of the raphe nuclei in 5-HT4 receptor knock-out mouse[J]. Eur J Neurosci, 2006, 24(4):1053-1062. [9] Doyle JM, Gao J, Wang J, et al.MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases[J]. Mol Cell, 2010, 39(6):963-974. [10] Mouri A, Sasaki A, Watanabe K, et al.MAGE-D1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation[J]. J Neurosci, 2012, 32(13):4562-4580. [11] Warner-Schmidt JL, Schmidt EF, Marshall JJ, et al.Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior[J]. Proc Natl Acad Sci USA, 2012,109(28): 11360-11365. [12] Egeland M, Warner-Schmidt J, Greengard P, et al.Co-expression of serotonin 5-HT1B and 5-HT4 receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum[J]. Neuropharmacology, 2011, 61(3): 442-450. [13] Anisman H, Du L, Palkovits M, et al.Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects[J]. J Psychiatr Neurosci, 2008, 33(2):131-141. [14] Svenningsson P, Kim Y, Warner-Schmidt J, et al.p11 and its role in depression and therapeutic responses to antidepressants[J]. Nat Rev Neurosci, 2013,14(10):673-680. [15] Warner-Schmidt JL, Flajolet M, Maller A, et al.Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation[J]. J Neurosci, 2009, 29(6):1937-1946. [16] Warner-Schmidt JL, Chen EY, Zhang X, et al.A role for p11 in the antidepressant action of brain-derived neurotrophic factor[J]. Biol Psychiat, 2010, 68(6):528-35. [17] Diez H, JJ Garrido,F Wandosell. Specific roles of Akt iso forms in apoptosis and axon growth regulation in neurons[J]. PLoS One, 2012, 7(4):e32715. [18] Leibrock C, Ackermann TF, Hierlmeier M, et al.Akt2 deficiency is associated with anxiety and depressive behavior in mice[J]. Cell Physiol Biochem, 2013, 32(3):766-777. [19] Pineyro G and Blier P. Autoregulation of serotonin neurons:role in antidepressant drug action[J]. Pharmacol Rev, 1999, 51(3):533-591. [20] Gunther L, Rothe J, Rex A, et al.5-HT1A-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test[J]. Neurop-harmacology, 2011, 61(3):433-441. [21] Richardson-Jones JW, Craige CP, Guiard BP, et al.5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants[J]. Neuron, 2010, 65(1):40-52. [22] Lemonde S, Turecki G., Bakish D, et al.Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide[J]. J Neurosci, 2003, 23(25):8788-8799. [23] Parsey RV, Olvet DM, Oquendo MA, et al.Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study[J]. Neuropsychopharmacol, 2006, 31(8): 1745-1749. [24] Alloui A, Olvet DM,?Oquendo MA, et al. TREK-1, a K+ channel involved in polymodal pain perception[J]. Embo J, 2006, 25(11):2368-2376. [25] Heurteaux C, Lucas G, Guy N, et al.Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype[J]. Nat Neurosci, 2006, 9(9):1134-1141. [26] Liou YJ, Lucas G., Guy N, et al.Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment[J]. Pharmacogenet and Genom, 2009, 19(10):735-741. [27] Datar P, Srivastava S, Coutinho E, et al.Substance P: Structure, function, and therapeutics[J]. Curr Top Med Chem, 2004, 4(1):75-103. [28] Froger N, Gardier AM, Moratalla R, et al.5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization[J]. J Neurosci, 2001, 21(20):8188-8197. [29] Santarelli L, Gobbi G, Debs P, et al.Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function[J]. Proc Natl Acad Sci USA, 2001, 98(4):1912-1917. [30] Frisch P, Srivastava S, Coutinho E, et al.Modulation of the CRH system by substance P/NKA in an animal model of depression[J]. Behv Brain Res, 2010, 213(1):103-108. [31] Burnet PWJ and PJ Harrison. Substance P (NK1) receptors in the cingulate carter in unipolar and bipolar mood disorder and schizophrenia[J]. Biol Psychiat, 2000, 47(1):80-83. [32] Stockmeier CA, Shi X, Konick L, et al.Neurokinin-I receptors are decreased in major depressive disorder[J]. Neuroreport, 2002, 13(9):1223-1227. [33] Freund TF, Katona I and Piomelli D. Role of endogenous cannabinoids in synaptic signaling[J]. Physiol Rev, 2003, 83(3):1017-1066. [34] Cassano T, Gaetani S, Macheda T, et al.Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice[J]. Psychoph-armacology, 2011, 214(2):465-476. [35] Bambico FR, Cassano T, Dominguez-Lopez S, et al.Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus[J]. Neuropsychophar-macol, 2010, 35(10):2083-2100. [36] Siuciak JA.The role of phosphodiesterases in schizophrenia: therapeutic implications[J]. CNS Drugs, 2008,22(12):983-993. [37] Schaefer TL, Braun AA, Amos-Kroohs RM, et al.A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects[J]. Genes Brain Behav, 2012, 11(5):614-622. [38] Levinson DF.The genetics of depression: a review[J]. Biol Psychiat, 2006, 60( 2):84-92. |